576 related articles for article (PubMed ID: 26708003)
1. Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.
Choudhury SR; Harris AF; Cabral DJ; Keeler AM; Sapp E; Ferreira JS; Gray-Edwards HL; Johnson JA; Johnson AK; Su Q; Stoica L; DiFiglia M; Aronin N; Martin DR; Gao G; Sena-Esteves M
Mol Ther; 2016 Apr; 24(4):726-35. PubMed ID: 26708003
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy.
Choudhury SR; Fitzpatrick Z; Harris AF; Maitland SA; Ferreira JS; Zhang Y; Ma S; Sharma RB; Gray-Edwards HL; Johnson JA; Johnson AK; Alonso LC; Punzo C; Wagner KR; Maguire CA; Kotin RM; Martin DR; Sena-Esteves M
Mol Ther; 2016 Aug; 24(7):1247-57. PubMed ID: 27117222
[TBL] [Abstract][Full Text] [Related]
3. More expansive gene transfer to the rat CNS: AAV PHP.EB vector dose-response and comparison to AAV PHP.B.
Dayton RD; Grames MS; Klein RL
Gene Ther; 2018 Aug; 25(5):392-400. PubMed ID: 30013186
[TBL] [Abstract][Full Text] [Related]
4. AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.
Liguore WA; Domire JS; Button D; Wang Y; Dufour BD; Srinivasan S; McBride JL
Mol Ther; 2019 Nov; 27(11):2018-2037. PubMed ID: 31420242
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Capsid Proteins Impact Transduction Efficiency of Haploid Adeno-Associated Virus Vectors.
Chai Z; Zhang X; Dobbins AL; Frost EA; Samulski RJ; Li C
Viruses; 2019 Dec; 11(12):. PubMed ID: 31835440
[TBL] [Abstract][Full Text] [Related]
6. Widespread transduction of astrocytes and neurons in the mouse central nervous system after systemic delivery of a self-complementary AAV-PHP.B vector.
Rincon MY; de Vin F; Duqué SI; Fripont S; Castaldo SA; Bouhuijzen-Wenger J; Holt MG
Gene Ther; 2018 Apr; 25(2):83-92. PubMed ID: 29523880
[TBL] [Abstract][Full Text] [Related]
7. Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System.
Gessler DJ; Tai PWL; Li J; Gao G
Methods Mol Biol; 2019; 1950():143-163. PubMed ID: 30783972
[TBL] [Abstract][Full Text] [Related]
8. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.
Müller OJ; Leuchs B; Pleger ST; Grimm D; Franz WM; Katus HA; Kleinschmidt JA
Cardiovasc Res; 2006 Apr; 70(1):70-8. PubMed ID: 16448634
[TBL] [Abstract][Full Text] [Related]
9.
Batista AR; King OD; Reardon CP; Davis C; Shankaracharya ; Philip V; Gray-Edwards H; Aronin N; Lutz C; Landers J; Sena-Esteves M
Hum Gene Ther; 2020 Jan; 31(1-2):90-102. PubMed ID: 31696742
[TBL] [Abstract][Full Text] [Related]
10. A combination of mutations enhances the neurotropism of AAV-2.
Xu J; Ma C; Bass C; Terwilliger EF
Virology; 2005 Oct; 341(2):203-14. PubMed ID: 16102794
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.
Saraiva J; Nobre RJ; Pereira de Almeida L
J Control Release; 2016 Nov; 241():94-109. PubMed ID: 27637390
[TBL] [Abstract][Full Text] [Related]
12. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system.
Burger C; Gorbatyuk OS; Velardo MJ; Peden CS; Williams P; Zolotukhin S; Reier PJ; Mandel RJ; Muzyczka N
Mol Ther; 2004 Aug; 10(2):302-17. PubMed ID: 15294177
[TBL] [Abstract][Full Text] [Related]
13. Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain.
Zhang X; Chai Z; Lee Dobbins A; Itano MS; Askew C; Miao Z; Niu H; Samulski RJ; Li C
Biomaterials; 2022 Feb; 281():121340. PubMed ID: 34998171
[TBL] [Abstract][Full Text] [Related]
14. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain.
Matsuzaki Y; Konno A; Mochizuki R; Shinohara Y; Nitta K; Okada Y; Hirai H
Neurosci Lett; 2018 Feb; 665():182-188. PubMed ID: 29175632
[TBL] [Abstract][Full Text] [Related]
15. Vector Affinity and Receptor Distribution Define Tissue-Specific Targeting in an Engineered AAV Capsid.
Martino RA; Wang Q; Xu H; Hu G; Bell P; Arroyo EJ; Sims JJ; Wilson JM
J Virol; 2023 Jun; 97(6):e0017423. PubMed ID: 37199615
[TBL] [Abstract][Full Text] [Related]
16. AAV Capsid-Promoter Interactions Determine CNS Cell-Selective Gene Expression In Vivo.
Powell SK; Samulski RJ; McCown TJ
Mol Ther; 2020 May; 28(5):1373-1380. PubMed ID: 32213322
[TBL] [Abstract][Full Text] [Related]
17. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain.
Deverman BE; Pravdo PL; Simpson BP; Kumar SR; Chan KY; Banerjee A; Wu WL; Yang B; Huber N; Pasca SP; Gradinaru V
Nat Biotechnol; 2016 Feb; 34(2):204-9. PubMed ID: 26829320
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus.
Warrington KH; Gorbatyuk OS; Harrison JK; Opie SR; Zolotukhin S; Muzyczka N
J Virol; 2004 Jun; 78(12):6595-609. PubMed ID: 15163751
[TBL] [Abstract][Full Text] [Related]
19. Transduction Profile of the Marmoset Central Nervous System Using Adeno-Associated Virus Serotype 9 Vectors.
Matsuzaki Y; Konno A; Mukai R; Honda F; Hirato M; Yoshimoto Y; Hirai H
Mol Neurobiol; 2017 Apr; 54(3):1745-1758. PubMed ID: 26884266
[TBL] [Abstract][Full Text] [Related]
20. Impact of capsid modifications by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction.
Naumer M; Popa-Wagner R; Kleinschmidt JA
J Gen Virol; 2012 Oct; 93(Pt 10):2131-2141. PubMed ID: 22764318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
